Navidea to Host Moderated Q&A Webcast with Management
February 01 2018 - 5:25PM
Business Wire
Webcast is scheduled with CFO Jed Latkin for
Tuesday, February 13th at 5:00 p.m. ET
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a company
focused on the development of precision immunodiagnostic agents and
immunotherapeutics, announced today that it will hold an
online Question & Answer (Q&A) Session with Jed Latkin,
Chief Financial and Operating Officer, and Fred Cope, Ph.D., Chief
Scientific Officer of Navidea, on Tuesday February 13, 2018 at 5:00
p.m. Eastern Time. Investors are invited to submit questions they
would like to hear answered
to ir@navidea.com or tpatel@edisongroup.com by
Friday, February 9, 2018.
From time to time, between quarterly conference calls, the
management will host Q&A webcasts so investors and potential
investors can learn more about the Company, its strategy, and its
products.
Event:
Navidea Q&A Session – February
2018
Date: Tuesday, February 13th, 2018
Time:
5:00 p.m. Eastern
US/Canada Toll-Free: 800-239-9838
Conference ID:
9621939
Webcast:
http://www.audio-webcast.com/cgi-bin/visitors.ssp?fn=visitor&id=5287
This ongoing Q&A series brings the Company closer to its
shareholder base and is designed to maintain a continued open forum
to highlight the Company’s clinical trial progress as well as the
many milestones Navidea hopes to achieve over the next several
quarters.
For the February 13 Q&A Session, Navidea invites all
interested investors to submit questions they would like to see
asked by Friday, February 9
to ir@navidea.com or tpatel@edisongroup.com.
About Navidea Biopharmaceuticals:
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
Manocept™ platform to enhance patient care by identifying the sites
and pathways of disease and enabling better diagnostic accuracy,
clinical decision-making, and targeted treatment. Navidea’s
Manocept platform is predicated on the ability to specifically
target the CD206 mannose receptor expressed on activated
macrophages. The Manocept platform serves as the molecular backbone
of Tc 99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. The development
activities of the Manocept immunotherapeutic platform are being
conducted by Navidea in conjunction with its subsidiary, Macrophage
Therapeutics, Inc. Navidea’s strategy is to deliver superior growth
and shareholder return by bringing to market novel products and
advancing the Company’s pipeline through global partnering and
commercialization efforts.
For more information, please
visit http://www.navidea.com.
Forward Looking Statements:
This release and any oral statements made with respect to the
information contained in this release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. We have based these forward-looking statements
largely on our current expectations and projections about future
events and financial trends affecting the financial condition of
our business. These forward-looking statements are subject to a
number of risks, uncertainties and assumptions, including, among
other things: general economic and business conditions, both
nationally and in our markets; our history of losses and
uncertainty of future profitability; the final outcome of the CRG
litigation in Texas; our ability to successfully complete research
and further development of our drug candidates; the timing, cost
and uncertainty of obtaining regulatory approvals of our drug
candidates; our ability to successfully commercialize our drug
candidates; our expectations and estimates concerning future
financial performance, financing plans and the impact of
competition; our ability to raise capital sufficient to fund our
development and commercialization programs; our ability to
implement our growth strategy; anticipated trends in our business;
advances in technologies; and other risk factors set forth in this
report and detailed in our most recent Annual Report on Form 10-K
and other SEC filings. You are urged to carefully review and
consider the disclosures found in our SEC filings, which are
available at www.sec.gov or at http://ir.navidea.com.
Investors are urged to consider statements that include the
words “will,” “may,” “could,” “should,” “plan,” “continue,”
“designed,” “goal,” “forecast,” “future,” “believe,” “intend,”
“expect,” “anticipate,” “estimate,” “project,” and similar
expressions, as well as the negatives of those words or other
comparable words, to be uncertain forward-looking statements. You
are cautioned not to place undue reliance on any forward-looking
statements, any of which could turn out to be incorrect. We
undertake no obligation to update publicly or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise after the date of this report. In light
of these risks and uncertainties, the forward-looking events and
circumstances discussed in this report may not occur and actual
results could differ materially from those anticipated or implied
in the forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180201006646/en/
Navidea Biopharmaceuticals, Inc.Jed Latkin,
614-973-7490CFO/COOjlatkin@navidea.comorEdison AdvisorsTirth Patel,
646-653-7035tpatel@edisongroup.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Sep 2023 to Sep 2024